Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (October 2026)
63 slides from Immatics's investor presentation, Oct 26, 2026
Slide 1: Immatics Corporate Presentation
© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 24, 2026
Slide 2: Forward-Looking Statement
Forward - Looking Statement 2 No Offer or Solicitation . This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shal
Slide 3: PRAME Is Expressed in More Than 50 Cancers
PRAME prevalence in selected indications PRAME Is Expressed in More Than 50 Cancers Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Data on file: PRAME target prevalence is based on a proprietary initial mass spec - guided expression threshold applied to RNAseq and/or IHC data (approximate
Slide 4: Immatics Is the Global Leader in Precision Targeting of PRAME
Immatics Is the Global Leader in Precision Targeting of PRAME • P RAME is an intracellular protein pre sented as a peptide on the surface of tumor cells by HLA molecules 1 • The PRAME peptide can be targeted by T - cell receptors (TCRs) engineered by Immatics, thus overcoming limitations of classica
Slide 5: Immatics has the Broadest PRAME Franchise
Target Indication Modality Product candidate 2L advanced melanoma Cell therapy Anzu - cel (IMA203) Uveal melanoma Cell therapy Anzu - cel (IMA203) Solid cancers Cell therapy Anzu - cel (IMA203) + mRNA - 4203 Gynecologic cancers Cell therapy IMA203CD8 Other so lid cancers Melanoma, gynecologic cancer
Slide 6: Broadest PRAME Franchise: Wave Overview and Addressable Patients
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 6 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), All patient numbers refer to PRAME+/HLA - A*02:01+ patients in the US and EU5; Source: Internal Forecast 2 026; EU5: France, Germany, Italy, Spain, Unite
Slide 7: Broadest PRAME Franchise: Status and Expected Milestones
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 7 PRAME Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Includes all benefits of Breakthrough Therapy Designation; b Pre - specified final analysis expected to be triggered upon the occurrence of a def
Slide 8: Target Product Profiles for Cell Therapy and Bispecifics
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 8 PRAME a Target product profile (TPP) in monotherapy in 2L or later settings post SOC at recommended phase 2 dose (“RP2D”) for develop me nt beyond Ph1b. Other factors such as mPFS (median progression free surv
Slide 9: PRAME Wave 1: Anzu-cel (IMA203) Market Entry in Advanced Melanoma
PRAME WAVE 1 Anzu - cel (IMA203) PRAME Cell Therapy Market Entry in Advanced Melanoma
Slide 10: Anzu-cel Opportunity: Market Entry in Advanced Melanoma
Anzu - cel (IMA203) Opportunity Anzu - cel (IMA203) PRAME Cell Therapy: Market Entry in Advanced Melanoma 10 2L unresectable or metastatic melanoma ~10K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), All patient numbers refer to
Slide 11: Positive Data and High Unmet Need
Positive Data and High Unmet Need 11 SUPRAME: Phase 3 randomized trial of anzu - cel vs. investigator choice in 2L advanced melanoma d ongoing (#NCT06743126) Phase 2 single arm cohort of anzu - cel in metastatic uveal melanoma ongoing (#NCT03686124) Anzutresgene autoleucel ( anzu - cel, formerly IMA
Slide 12: Ph1b Study of Anzu-cel: Patient Journey
Ph 1b Study of Anzu - cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Patient Journey 12 HLA - A*02:01 Testing Blood sample Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Anzu - cel (IMA203) One - time infusion Lymphodepletion b Low
Slide 13: Patients with Metastatic Melanoma in High Unmet Need Settings
Patients with Metastatic Melanoma in High Unmet Need Settings: PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 13 a Mucosal melanoma n=2; melanoma of unknown primary n=1. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhib ito r; LDH, lactate dehydrogenase; TCR, T - cell
Slide 14: Anzu-cel Expected and Manageable Tolerability Profile
Anzu - cel (IMA203) PRAME Cell Therapy Demonstrated an Expected and Manageable Tolerability Profile 14 All Melanoma ( n =33) TEAEs in ≥30% Grade ≥3 Any grade Preferred term, n (%) 0 22 (67) Nausea 6 (18) 17 (52) ALT/AST increased 3 (9) 14 (42) Rash a 0 13 (39) Fatigue 0 12 (36) Constipation 3 (9) 10
Slide 15: Anzu-cel Rapid and Deep Responses
Anzu - cel (IMA203) PRAME Cell Therapy Induced Rapid and Deep Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 15 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel n=33 n=3 n=16 n=14 5 6 % (18/3 2 ) 1/3 6 7 % (10/15) 5 0 % (7/1 4 ) cORR b 6 4 %
Slide 16: Anzu-cel Durable Responses in Melanoma
Change in Sum of Longest Diameter of Target Lesions from Baseline [%] Months Post T - cell Infusion Ongoing response at 39.6 mo Response until 32.9 mo BL PR cCR cPR PR SD PD Ongoing Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastat
Slide 17: Anzu-cel Durable Responses: PFS and OS
Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 17 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel Median Progression Free Survival Median Overall Survival All Melanoma a n=33 Uveal Mela
Slide 18: Anzu-cel in Melanoma: Overview of Competitive Studies
These data are derived from different clinical trials at different points in time with differences in trial design and patien t p opulations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted. Anzu - cel (IMA203) PRAME Cell Therapy in
Slide 19: Anzu-cel Enhanced mPFS of >1 Year in Patients with Deep Responses
Anzu - cel (IMA203) PRAME Cell Therapy Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses 19 Data cutoff Sep 24, 2025 Log - rank: 0.006 Anzutresgene autoleucel (anzu - cel, formerly IMA203), b, billion; ND, not defined; mFU , median follow - up; mPFS , median progression - free surviv
Slide 20: SUPRAME: Randomized Ph3 Trial of Anzu-cel
TRIAL DESIGN Expected SUPRAME Trial Analyses SUPRAME: A Randomized Ph3 Trial of Anzu - cel (IMA203) PRAME - directed TCR T - cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI Actively Enrolling across North America and Europe 20 Anzutresgene autoleucel ( anzu - ce
Slide 21: Cell Therapy Manufacturing Facility To Support Planned BLA
Cell Therapy Manufacturing Facility To Support Planned Anzu - cel BLA and Commercialization 21 Anzutresgene autoleucel ( anzu - cel, formerly IMA203); BLA: Biologics License Application PRAME Wave 1: anzu - cel • ~100,000 sq ft s tate - of - the - art research & GMP manufacturing facility • Modular
Slide 22: PRAME Wave 2: IMA203CD8 Expansion to all Advanced PRAME Cancers
PRAME WAVE 2 IMA203CD8 PRAME Cell Therapy Expansion to all Advanced PRAME Cancers
Slide 23: IMA203CD8: Expansion of Commercial Opportunity
IMA203CD8 PRAME Cell Therapy: Expansion of Commercial Opportunity to all Advanced PRAME+ Solid Tumors 23 All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Internal Forecast 2026; EU5: France, Germany, Italy, Spain, United Kingdom 1 Bajwa et al. 2021 Jo
Slide 24: Towards Proof-of-concept for Tumor-agnostic Targeting of PRAME Cancers
Towards Proof - of - concept for Tumor - agnostic Targeting of PRAME Cancers with IMA203CD8 24 a Being conducted at Hopp Children's Cancer Center Heidelberg ( KiTZ ), Germany; cPR , confirmed partial response; IIT, investigator - initiated trial; TEAE, treatment - emergent adverse events Summary: IM
Slide 25: Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors
Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors 25 PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer, melanoma, and synovial sarcoma IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine
Slide 26: IMA203CD8: Patient Disposition
IMA203CD8 PRAME Cell Therapy: Patient Disposition 26 Safety Population a N=98 Efficacy - evaluable Population b n=90 Gynecologic Indications n=27 Melanoma n=44 Synovial Sarcoma n=12 Other n=7 n=7 n=20 n=28 n=16 n=11 n=1 n=2 n=5 <DL4c ≥DL4c Gynecologic indications include ovarian cancer and uterine c
Slide 27: IMA203CD8: Baseline Characteristics
IMA203CD8: Baseline Characteristics 27 Efficacy - evaluable Population b Safety Population a Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecologic Indications n=27 All N=98 56 (38 - 71) 46 (20 - 66) 62 (23 - 85) 58 (35 - 75) 58 (20 - 85) Median age (range), years 4 (57) 4 (33) 22 (50) 27 (100) 6
Slide 28: IMA203CD8: Treatment Experience
IMA203CD8: Treatment Experience 28 Efficacy - evaluable Population b Safety Population a On Study Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecologic Indications n=27 All N=98 1.95 (1.47 - 10.00) 1.59 (0.89 - 10.00) 1.67 (0.44 - 11.80) 3.55 (0.47 - 12.50) 1.81 (0.44 - 12.50) Total infused dose
Slide 29: Tolerability of IMA203CD8 in Advanced Solid Tumors
Tolerability of IMA203CD8 in Advanced Solid Tumors 29 • Most frequent TEAEs were cytopenias associated with lymphodepletion • CRS was mostly grade 1 - 2 • DLTs in 4 of 98 patients: 1. DL4b: grade 4 neurotoxicity/CRS with grade 3 HLH 2. DL4b: grade 3 CRS 3. DL5: grade 3 ICANS b 4. DL7: grade 4 skin i
Slide 30: Tumor Reduction Achieved by IMA203CD8 Across Dose Levels
'DWDFXW RII 3DWLHQWVDUHRUGHUHGE\EHVWSHUFHQWDJHFKDQJHZLWKLQHDFKVXEJURXS 6XEJURXSRUGHU 6HOHFWHGVXEJURXSEORFNV :DWHUIDOO3ORW 2QJRLQJ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67
Slide 31: Changes in Tumor Size Over Time after IMA203CD8
Changes in Tumor Size Over Time after Treatment with IMA203CD8 31 3' 3' %DVHOLQH %DVHOLQH 35 35 0RQWKVSRVW7FHOOLQIXVLRQ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP%DVHOLQH >@ 3' 6' 35 F35 &5 F&5 %HVWRYHUDO
Slide 32: Responses of Metastatic Lesions after IMA203CD8
Responses of Metastatic Lesions after Treatment with IMA203CD8 32 Melanoma Gynecologic indications Synovial sarcoma Other n=87 a /HVLRQ %HVW &KDQJHIURP%DVHOLQHSHU7DUJHW Q $EGRPHQ 3HULWRQHXP Q /LYHU Q /XQJ Q /\PSKQRGH Q 2WKHU 2WKHUV 6\QRYL
Slide 33: Antitumor Activity of IMA203CD8 at Higher Doses in Gynecologic Indications
0RQWKVSRVW7FHOOLQIXVLRQ %DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP 3' %DVHOLQH 35 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 2QJRLQJ 6SLGHU 3RSXODWLRQ (IILFDF\$QDO\VLV6HW *\Q2QF%XQGOH ,0$
Slide 34: IMA203CD8 Ongoing Trials and Development Approach
IMA203CD8 Ongoing Trials and Development Approach 34 a Data on file. b Clinical data as part of an individual experimental treatment attempt with a TCR T - cell therapy in a pediatric patient using Imm atics PRAME - directed TCR published in Mair K, Rossi C, Westhoff JH, et al. PRAME - Specific T -
Slide 35: PRAME Wave 3: IMA402 Expansion to Earlier-Line PRAME Cancers
PRAME WAVE 3 IMA402 PRAME Bispecific Expansion to Earlier - Line PRAME Cancers
Slide 36: IMA402 Opportunity
IMA402 Opportunity 36 a Half - life calculated by non compartmental analysis (NCA); All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025 based on initial threshold for all indications except for sqNSCLC (optimized threshold considered for further development due t
Slide 37: IMA402 PRAME Bispecific Summary: Phase 1 Dose Escalation Study
Cancer Cell IMA402 PRAME Bispecific Summary: Phase 1 Dose Escalation Study 37 Tolerability Activity & Duration of Response Pharmacokinetics Development Potential Favorable tolerability profile Most frequent treatment - related AEs are low - grade CRS and expected & transient lymphopenia • Promising
Slide 38: Phase 1/2 Trial Design to Evaluate IMA402
Phase 1 Phase 1/2 Trial Design to Evaluate IMA402 PRAME Bispecific 38 • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • MTD not reached per adaptive BLRM model • q1w step dosing (3 doses) up to target dose b • q2w dosing from week
Slide 39: Demographics: Heavily Pretreated Patient Population in IMA402 Trial
Demographics: Heavily Pretreated Patient Population Enrolled in IMA402 Trial 39 Efficacy Population Safety Population n=40 N=126 Baseline Characteristics 27 - 26, 1, 0 8 5 - 2, 2, 1 78 - 62, 13, 3 31 17 - 7, 6, 4 Indication, n Melanoma - cutaneous, uveal, unknown primary Ovarian cancer Other - endom
Slide 40: Safety Profile of IMA402 Across All Indications and Dose Levels
Safety Profile of IMA402 Across All Indications and Dose Levels (N=126) 40 AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRS, cytokine release syndrome; ICANS, imm une effector - cell associated neurotoxicity syndrome; TEAE, treatment - emergent AE; TRAE, treatme
Slide 41: Efficacy of IMA402 ± Pembrolizumab Across All Indications
Efficacy of IMA402 ± Pembrolizumab Across All Indications in the Efficacy Population 41 IMA402 monotherapy IMA402 + pembrolizumab Melanoma a Ovarian cancer Other indications b BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment Confirmed responses in ICI - pretreate
Slide 42: IMA402: Exploratory Analysis of PRAME Levels and Disease Outcome
IMA402 PRAME Bispecific: Exploratory Analysis of PRAME Levels and Disease Outcome in Efficacy Population 42 PRAME mRNA expression relative to threshold PRAME low : 1 - 3x expression level PRAME high : >3x expression level PRAME negative: below threshold n=40 Tumor Reduction Efficacy Population All I
Slide 43: IMA402 PRAME Bispecific: Patient Disposition
IMA402 PRAME Bispecific: Patient Disposition 43 Efficacy Population n=40 PRAME low n=9 a PRAME high n=31 Melanoma n=22 IMA402 Monotherapy n=20 IMA402 + Pembrolizumab n=2 Ovarian Cancer n=6 Other b n=3 • Exploratory analysis in efficacy population based on qPCR expression levels • All responders c wi
Slide 44: Efficacy of IMA402 ± Pembrolizumab by PRAME Expression
Efficacy of IMA402 ± Pembrolizumab by PRAME Expression 44 BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment IMA402 monotherapy IMA402 + pembrolizumab Melanoma a Ovarian cancer Other indications b Ovarian Cancer Melanoma All Indications 3/6 32% (7/22) 32% (10/31) c
Slide 45: Durability of Responses with IMA402 in PRAME high Melanoma
Durability of Responses with IMA402 ± Pembrolizumab in PRAME high Melanoma All Patients with Melanoma in the Efficacy Population Received prior ICI 45 32% (7/22) cORR 12.5 mo 16.8 mo mDOR mFU n=22 Not reached 8.8 mo mOS mFU 91% 1 - year OS rate Ongoing patients were censored at the data cutoff for O
Slide 46: PRAME Prevalences for IMA402 Development in Selected Indications
PRAME Prevalences for IMA402 Development in Selected Indications 46 Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402 PRAME high based on actual in - house data PRAME high TCGA PRAME low+high TCGA a Indication >80% (n=136) 92% 95% Cutaneous melanoma 60% - 95% (n=15) 95% 97%
Slide 47: Outlook: Liquid Biopsy for Patient Selection
Outlook: Liquid Biopsy for Patient Selection 47 • Proprietary liquid biopsy assay for patient selection • Few millilitres of blood sufficient • Fast, sensitive and reliable detection of PRAME in blood • Representative PRAME levels across all tumor lesions prior to treatment start Best Overall Respon
Slide 48: Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402
Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402 Dual Targeting 48 Data on file - dot plot: PRAME and MAGEA4/8 mRNA expression in stage III/IV sqNSCLC TCGA samples (TPM, log - scale), PRAME and MAGEA4/8 target prevalences are based on an optimized proprietary target expression th re
Slide 49: IMA402 Development Path to Deliver an Off-the-Shelf PRAME Therapy
IMA402 Development Path to Deliver an Off - the - Shelf PRAME Therapy 49 IMA402 Cohorts in Phase 1b Clinical Evaluation IMA402 + ICI a 2L melanoma IMA402 monotherapy 2L melanoma IMA402 + pembrolizumab Gynecologic cancers IMA402 + IMA401 sqNSCLC IMA402 + decitabine Ovarian cancer, melanoma Monotherap
Slide 50: IMA401 MAGEA4/8 Bispecific: Maximizing the Potential of Bispecifics Combination
Entering the PRAME Franchise IMA401 MAGEA4/8 Bispecific Maximizing the Potential of Bispecifics Combination
Slide 51: IMA401 MAGEA4/8 Bispecific Summary: Phase 1 Dose Escalation Study
Cancer Cell MAGEA4/8 IMA401 MAGEA4/8 Bispecific Summary: Phase 1 Dose Escalation Study 51 1 at RP2D of 1 - 2 mg; AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; DCR: disease control rate; ICI : immune checkpoint inhibitor; HNSCC: Head and neck squamous
Slide 52: Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 52 EudraCT No 2021 - 004326 - 30; NCT05359445; a Step dosing introduced at dose levels ≥1 mg, low - dose dexamethasone partially used as preventive measure for initial doses as ap plied for other bispecific T - cell engagers; ability to increas
Slide 53: Phase 1 Basket Trial of IMA401: Baseline Characteristics
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 53 a Includes small molecule drugs and antibodies . b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); adNSCLC , adenocarcinoma non - small cell lung cancer ; ECOG, Eastern Cooperative Oncology Group; GCT, germ ce
Slide 54: Tolerability of IMA401 Monotherapy
Tolerability of IMA401 Monotherapy 54 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3; b in patients with and without dexamethasone pre - medication , one possibly related
Slide 55: Tolerability of IMA401 at RP2D ± Pembrolizumab
Tolerability of IMA401 at RP2D ± Pembrolizumab 55 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3 and typical ICI - associated toxicities ; b IMA401 dose in pembrolizumab e
Slide 56: Anti-Tumor Activity of IMA401 at RP2D ± Pembrolizumab
Anti - Tumor Activity of IMA401 at RP2D ± Pembrolizumab 56 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients wi
Slide 57: Durable Responses to IMA401 in Patients with H&N Cancer
Durable Responses to IMA401 ± Pembrolizumab in Patients with H&N Cancer 57 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, inclu
Slide 58: Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC
Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC 58 a Treatment start 5 weeks after last prior systemic therapy; scans courtesy of treating physician Prof. Dr. Martin Wermke , TU Dresden; BOR, best overall response; ICI, immune checkpoint inhibitor; PR, partial response; Pt, pa
Slide 59: Appendix
Appendix Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com
Slide 60: Anzu-cel Ph1 Trial: Significant Shift in PFS and OS
Anzu - cel Ph1 Trial: Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS of 16 Months in Melanoma Efficacy Population 60 Progression Free Survival Data cutoff Sep 24, 2025 Overall Survival mPFS N 2.6 months 11 Dose Escalation 6.1 months 33 Dose Expansion
Slide 61: Potential of PRAME-Directed Therapies in Solid Cancers
Potential of PRAME - Directed Therapies in Solid Cancers PRAME Target Expression and Prevalences in Selected Solid Cancer Types Hukelmann et al., SITC 2022, updated prevalences as of May 2025; a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided initial expression thr
Slide 62: IMA203CD8 Shows Broad Clinical Activity across Diverse PRAME+ Solid Tumors
IMA203CD8 Shows Broad Clinical Activity across Diverse PRAME+ Solid Tumors Clinical Activity in PRAME+ T umors with D istinct P athology / Biology 62 Clinical activity to date spans different PRAME levels, tumor biologies and tumor immune phenotypes, supporting broad applicability of IMA203CD8 for P
Slide 63: Thank you!
Thank you! Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com